 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. Nasdaq: INFI Infinity or the Company, a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced the closing of the sale of 24,150,000 shares of its common stock at a public offering price of 3.80 per share in its previously announced 